VOR Vor Biopharma Inc.

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, Vor designs these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells. Vorís platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell treatments.

$44.94  -9.14 (-16.90%)
As of 02/26/2021 15:59:15 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA

02/04/2021
34,641,360
494,174
$1,557,475,546
0.00%
SEC Edgar Online
10-Q
10-K



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
24.65
0.00
-6.16%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy